Suppr超能文献

吩噻嗪类和萘磺酰胺类药物诱导的α2-巨球蛋白和表皮生长因子表面结合丧失

Loss of alpha 2-macroglobulin and epidermal growth factor surface binding induced by phenothiazines and naphthalene sulfonamides.

作者信息

DiPaola M, Keith C H, Feldman D, Tycko B, Maxfield F R

出版信息

J Cell Physiol. 1984 Feb;118(2):193-202. doi: 10.1002/jcp.1041180212.

Abstract

We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (EGF) in fibroblasts. The loss of alpha 2-macroglobulin receptors is independent of receptor occupancy and is rapidly reversed upon removal of these agents from the culture medium. The extent of EGF receptor loss is less than for alpha 2-macroglobulin, and the EGF receptors do not reappear at the surface when W-7 is removed. Receptor loss was measured as a change in the capacity for binding iodinated ligands; no change in affinity of binding was observed. This receptor loss could reflect inactivation of receptors or internalization. W-7 did not induce a loss of cell surface beta 2-microglobulin, a membrane protein which is excluded from coated pits and which is not internalized, indicating that the effect of W-7 was specific for membrane receptors and not a result of bulk depletion of plasma membrane. The loss of alpha 2-macroglobulin and EGF receptors occurs at concentrations which do not cause an increase in the pH of endocytic vesicles or the cytoplasm, indicating that these agents act by a mechanism distinct from the effect of other weak bases. Since both TFP and W-7 are potent inhibitors of calmodulin, we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors. Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin. These data indicated that cell surface receptor numbers can be regulated by a cellular component that is not cytoplasmic calmodulin but that shares some drug sensitivities with calmodulin.

摘要

我们发现某些萘磺酰胺类化合物[如N-6(-氨基己基)-5-氯-1-萘磺酰胺(W-7)]和吩噻嗪类化合物[如三氟拉嗪(TFP)]可导致成纤维细胞表面的α2-巨球蛋白和表皮生长因子(EGF)受体丧失。α2-巨球蛋白受体的丧失与受体占据无关,并且当从培养基中去除这些药物后,该丧失会迅速逆转。EGF受体丧失的程度小于α2-巨球蛋白受体,并且当去除W-7后,EGF受体不会重新出现在细胞表面。受体丧失通过结合碘化配体能力的变化来衡量;未观察到结合亲和力的改变。这种受体丧失可能反映受体失活或内化。W-7不会导致细胞表面β2-微球蛋白丧失,β2-微球蛋白是一种膜蛋白,不被包被小窝摄取且不会被内化,这表明W-7的作用对膜受体具有特异性,而非质膜大量消耗的结果。α2-巨球蛋白和EGF受体的丧失发生在不会导致内吞小泡或细胞质pH升高的浓度下,这表明这些药物的作用机制与其他弱碱的作用机制不同。由于TFP和W-7都是钙调蛋白的有效抑制剂,我们研究了钙调蛋白抑制是否是受体丧失的原因。三条证据表明钙调蛋白抑制并非结合和内吞作用受抑制的原因:1) 异丙嗪是一种对钙调蛋白抑制作用较弱的吩噻嗪类化合物,在抑制内吞作用方面几乎与TFP一样有效;氯咪巴唑是几种钙调蛋白功能的有效抑制剂,但不会导致结合丧失;2) 向细胞中微量注射钙调蛋白并不能逆转W-7的作用;通过压力微量注射,我们向单个沙鼠纤维瘤细胞中引入了比天然水平高100倍的钙调蛋白;使用罗丹明标记的α2-巨球蛋白,我们发现注射和未注射细胞中W-7诱导的受体介导内吞作用的抑制效果相同;3) 我们向细胞中注射钙调神经磷酸酶(一种钙调蛋白结合蛋白)(1 - 3 pg/细胞),未观察到对罗丹明标记的α2-巨球蛋白受体介导内吞作用有任何影响。这些数据表明细胞表面受体数量可由一种细胞成分调节,该成分不是细胞质钙调蛋白,但与钙调蛋白具有一些药物敏感性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验